Mikell Jarratt, MD
Pulmonary Disease · Gastonia, NCNPI 1497785604
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,100 of the $45,157 with a category attached, or 66.7%. GSK accounts for 67.9% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $15,776 and has fallen 89.2% since, to $1,703 in 2025. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 817 payments — averaging $55.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$31K
- Viiv Healthcare Company$2K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- Merck$970
- Novo Nordisk$763
- plus $8K from 54 others
Across 409 payments — averaging $4122.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$436K
- Novartis$353K
- GSK$228K
- Mallinckrodt Enterprises LLC$123K
- Merck$103K
- Astrazeneca AB$81K
- plus $362K from 11 others
What the payments were for
- Speaking & faculty fees$30,10067%
- Travel & lodging$6521%
- Food & beverage$14,31832%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$14,220
- ANORO$7,405
- ANORO ELLIPTA$7,200
- MK-7264$652
- Arikayce$122
How this compares
$45,157 in reported general payments places this provider in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 570 | $482,002 |
| Breo ElliptaFluticasone/Vilanterol | 270 | $147,414 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 179 | $127,278 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 148 | $76,449 |
| SymbicortBudesonide/Formoterol Fumarate | 187 | $63,421 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 90 | $50,620 |
| Spiriva RespimatTiotropium Bromide | 47 | $34,062 |
| Spiriva HandihalerTiotropium Bromide | 52 | $33,947 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 826 | $23,206 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 163 | $17,431 |
| Wixela InhubFluticasone Propion/Salmeterol | 142 | $16,672 |
| Arnuity ElliptaFluticasone Furoate | 29 | $10,091 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $10,091 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 47 | $9,625 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $9,430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $30,643 | $690,128959 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,497 | $190,700366 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,145 | $120,602211 claims |
| MerckDulera | $970 | $9,40520 claims |
| PfizerEliquis | $178 | $6,84012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Gastonia
- Raed SuleimanGastonia$195K
- Emeka EziriGastonia$28K
- Anup BanerjeeGastonia$19K
- Jay HendlerGastonia$17K
- Azeem ElahiGastonia$17K
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.